Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019-Reference-Cited by-同舟云学术

Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019

Published:2021-03-26 Issue:2 Volume:163 Page:e293-e309
ISSN:0304-3959
Container-title:Pain
language:en
Short-container-title:PAIN

Author:

Safiri Saeid,Pourfathi Hojjat,Eagan Arielle,Mansournia Mohammad Ali,Khodayari Mohammad Taghi,Sullman Mark J.M.,Kaufman Jay,Collins Gary,Dai Haijiang,Bragazzi Nicola Luigi,Kolahi Ali-Asghar

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),Neurology

Reference42 articles.

1. The association between migraine and physical exercise;Amin;J Headache Pain,2018

2. Migraine in adolescents: association with socioeconomic status and family history;Bigal;Neurology,2007

3. Migraine: epidemiology, burden, and comorbidity;Burch;Neurol Clin,2019

4. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study;Buse;Headache,2012

5. Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study;Buse;J Headache Pain,2020

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel CLIPS-based medical expert system for migraine diagnosis and treatment recommendation;Kuwait Journal of Science;2025-01

2. Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome;Neurology;2024-09-24

3. Effect of Smoking on the Development of Migraine in Women: Nationwide Cohort Study in South Korea;JMIR Public Health and Surveillance;2024-08-23

4. Inflammo-immune perspective on the association of eight migraine risk factors with migraine: a multi-omics Mendelian randomization study;Frontiers in Neurology;2024-08-07

5. Health care resource utilization and direct costs incurred over 24 months after initiating galcanezumab or standard-of-care preventive migraine treatments in the United States;Journal of Managed Care & Specialty Pharmacy;2024-08